De behandeling van angina pectoris met nitraten

Nederlands Tijdschrift voor Geneeskunde

Volumn 140, Issue 15, 1996, Pages 819-822

  Van Wijngaarden, J ^a   Van Veldhuisen, D J ^a   De Graeff, P A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NITRIC ACID DERIVATIVE;

ANGINA PECTORIS; HEMODYNAMICS; HUMAN; ORAL DRUG ADMINISTRATION; SHORT SURVEY; TRANSDERMAL DRUG ADMINISTRATION;

ANGINA PECTORIS; DRUG TOLERANCE; HEADACHE; HEMODYNAMIC PROCESSES; HUMANS; NITRATES;

EID: 0029923560     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Brunton TL. On the use of nitrite of amyl in angina pectoris. Lancet 1867;ii:7-8
2. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6
3. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987;61:866-79.
4. Myers PR, Minor RL jr, Guerra R Jr, Bates JN, Harrison DG. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990; 345:161-3.
5. Bel EE de. Stikstofoxyde: nieuw licht op vele klinische syndromen. Ned Tijdschr Geneeskd 1994;138:650-6.
6. Ignarro LJ, Lipplon H, Edwards JC, Bancos WH, Hyman AL, Kadowitz PJ, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-49.
7. Harrison DG, Bates JN. The nitrovasodilators. New ideas about old drugs. Circulation 1993;87:1461-7.
8. Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates. Am Heart J 1985;110:216-24.
9. Ahlner J, Andersson RG, Torfgard K, Axelsson KL Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol Rev 1991; 43:351-423.
10. Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation 1990;81:850-9.
11. Feldman RL, Pepine CJ, Curry jr RC, Conti CR. Coronary arterial responses to graded doses of nitroglycerin. Am J Cardiol 1979;43: 91-7.
12. Brown BG, Bolsen EL, Dodge HT. Dynamic mechanisms in human coronary artery stenosis. Circulation 1984;70:917-22.
13. Noonan PK, Benet LZ. Incomplete and delayed bioavailability of sublingual nitroglycerin. Am J Cardiol 1985;55:184-7.
14. Goldberg L. Pharmacological properties of sorbide dinitrate. Acta Physiol Scand 1948;15:173-87.
15. Parker JO, Vankoughnett KA, Farrell B. Nitroglycerin lingual spray clinical efficacy and dose-response relation. Am J Cardiol 1986;57:1-5.
16. Lange RL, Reid MS, Tresch DD, Keelan MH, Bernhard VM, Coolidge G. Nonatheromatous ischemic heart disease following withdrawal from chronic industrial nitroglycerin exposure. Circulation 1972;46:666-78.
17. May DC, Popma JJ, Black WH, Schaefer S, Lee HR, Levine BD, et al. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 1987;317:805-9.
18. Steering Committee. Transdermal nitroglycerin cooperative study. Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Am J Cardiol 1991;68: 1263-73.
19. Ferratini M, Pirelli S, Merlini P, Silva P, Pollavini G Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina. a comparison with a continuous schedule. Eur Heart J 1989; 10:998-1002
20. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:786-95.
21. Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval. Circulation 1995;91:973-8
22. Olsson G, Allgén J, Amtorp O, Nyberg G, Parker JO. Absence of pre-dose rebound phenomena with once daily 5-ISMN in a controlled-release formulation. Eur Heart J 1992;13:814-7.
23. Freedman SB, Daxini BV, Noyce D, Kelly DT. Intermittent transdermal nitrates do not improve ischemia in patients taking betablockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period. J Am Coil Cardiol 1995;25:349-55.
24. Iversen HK., Nielsen TH, Garre K, Tfelt-Hansen P, Olesen J. Dosedependent headache response and dilatation of limb and extracranial arterics after three doses of 5-isosorbide-mononitrate. Eur J Clin Pharmacol 1992;42:31-5.
25. Seabra-Gomes R, Aleixo AM, Adao M, Machado FP, Mendes M. Bruges G, et al. Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris Am J Cardiol 1990;65:1308-12.